Bevifimod

Names

[ CAS No. ]:
2223113-32-2

[ Name ]:
Bevifimod

Biological Activity

[Description]:

Bevifimod (PRTX-100) is a highly purified form of Staphylococcal protein A (SpA). Bevifimod can be used for idiopathic thrombocytopenic purpura (ITP) research[1][2].

[Related Catalog]:

Research Areas >> Cardiovascular Disease
Signaling Pathways >> Others >> Others
Research Areas >> Inflammation/Immunology

[In Vitro]

Bevifimod（PRTX-100；250、25 和 2.5 ng/mL；48 小时）抑制外周血单核细胞 (PBMC) 中人单核细胞对 W632 调理血小板的吞噬作用[1]。

[In Vivo]

Bevifimod (PRTX-100; 2.5-250 μg/kg; i.v.; once every two weeks; for 4 weeks) increases platelet counts to within normal levels within 1-2 weeks and none of the mice died[2]. Animal Model: SCID mice bearing immune thrombocytopenia (ITP)[2] Dosage: 2.5 μg/kg, 25 μg/kg, 250 μg/kg Administration: i.v.; once every two weeks; for 4 weeks Result: Raised platelet counts in a well-established murine model of ITP.

[References]

[1]. ChrisYatkoBS, et al. PRTX-100 Inhibits Platelet Phagocytosis In Vitro. Blood (2006) 108 (11): 1081.

[2]. John W. Semple, et al. Successful Treatment of Thrombocytopenia with Staphylococcal Protein A (PRTX-100) in a Murine Model of Immune Thrombocytopenia (ITP). Blood (2015) 126 (23): 1045.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds